Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on iRhythm (IRTC) to $147 from $160 and keeps an Overweight rating on the shares.The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- BTIG maintains iRhythm estimates after CMS fee schedule proposal
- iRhythm Technologies Announces Board Member Changes
- iRhythm appoints Karen McGinnis, Kevin O’Boyle to board of directors
- iRhythm announces results from two large-scale real-world studies at ADA 2025
- iRhythm price target raised to $165 from $140 at BTIG